A double-blind placebo-controlled study of rolipram in depressed in-patients.
In a double-blind study, rolipram, a new phosphodiesterase inhibitor, was com pared to placebo in 20 hospitalized depressed patients. There was a high rate of non- completion (11 out of 20) at 28 days. No difference was found in the clinical improvement between the two groups.